There is currently no medication approved by the U.S. Food and Drug Administration specifically to treat cocaine use disorder. That does not mean medication can never have a role in a person’s care. Clinicians may treat co-occurring conditions, manage particular symptoms, or consider an off-label option after assessing the evidence and individual circumstances. The important question is what a proposed medicine is intended to do and how its benefit and risks will be reviewed.
The FDA’s current stimulant information states that FDA-approved pharmacological treatments for stimulant use disorders are not yet available. This status was checked on October 18, 2026. Do not interpret a clinic’s use of a prescription medicine, a research finding, or a trial registration as proof that the medicine has regulatory approval for cocaine use disorder.
Begin by identifying the treatment target
Ask whether the medicine is being proposed for cocaine use itself, a diagnosed mental health condition, sleep or another symptom, or a separate medical problem. These are different purposes. An antidepressant prescribed for depression is not automatically a cocaine addiction medication, even if treating depression is an important part of the overall plan.
Ask how the target was assessed and what improvement would look like. The answer might concern a particular symptom, functioning, treatment participation, or substance use outcome. A vague promise to balance brain chemistry is not enough to explain an individual prescription. The clinician should be able to describe the intended benefit in terms you can understand and review.
Bring the full medication and substance use history. Include prescribed stimulants, alcohol, benzodiazepines, opioids, cannabis, supplements, and nonprescribed products. Tell the clinician what you actually take and what has changed. A treatment decision made without this information may not reflect the relevant risks or the reason symptoms are occurring.
Understand what off-label means
Off-label prescribing means a medicine is used for a purpose or in a way that is not included in its approved labeling. It does not automatically mean the treatment is inappropriate, and it does not mean the use is approved for that condition. Ask the prescriber to explain the evidence, limitations, alternatives, and why the option may fit your particular circumstances.
The ASAM and AAAP stimulant guideline discusses selected off-label medication options with conditional recommendations and clinical qualifications. Those recommendations should not be converted into a universal drug list for patients to try. The relevant choice depends on assessment, co-occurring conditions, monitoring capacity, and professional judgment.
Ask how strong the supporting evidence is and whether it comes from people similar to you. Does the study concern cocaine, another stimulant, or a mixed population? Was the medicine used with behavioral treatment? A result in one context should not be assumed to apply unchanged to another. The clinician can explain what is known and what remains uncertain.
Behavioral treatment remains central
The SAMHSA stimulant treatment guide describes evidence-based behavioral approaches, including contingency management and cognitive behavioral treatment. Medication discussions should connect to those care needs rather than replace them with a prescription-only promise. Ask which treatment will address the situations, habits, and practical barriers involved in your cocaine use.
Our contingency management guide explains a structured incentive-based approach, while the CBT guide describes work on thoughts, behaviors, and practiced responses. A clinician may combine interventions based on the assessment. You should understand what each component contributes and how the plan will be reviewed as a whole.
If a service presents a medicine as a complete cure or a way to avoid all ongoing treatment, request the exact evidence and approval information. Be cautious about guaranteed results, secret protocols, or claims that every patient needs the same combination. Appropriate prescribing can be explained without hiding behind proprietary language or promising certainty that the evidence does not support.
Co-occurring conditions deserve their own assessment
Depression, anxiety, ADHD, bipolar symptoms, psychosis, and other concerns may affect treatment. A clinician should consider whether symptoms predated cocaine use, occurred during intoxication or withdrawal, or have another explanation. The timing is important but does not settle the diagnosis alone. Ask what the working explanation is and when it will be reassessed.
NIMH’s co-occurring disorders guidance supports assessment and treatment of mental health and substance use concerns together. A cocaine history should not automatically lead to stopping appropriate treatment for another condition. Equally, an old psychiatric diagnosis should not prevent review of new symptoms or unsafe medication use.
If an established prescription is involved, contact the responsible prescriber before making changes. Explain any missed doses, extra use, or concerns about the combination with cocaine. Do not borrow another person’s medication to test whether a diagnosis fits or whether it reduces cravings. The treatment decision requires an individual assessment and a clear monitoring plan.
Ask about safety and monitoring before starting
Discuss the relevant medical history, other medicines, and prior adverse reactions. Ask which checks are needed before and during treatment and why. The monitoring plan should be specific to the proposed medicine and your circumstances. It should not be reduced to a generic statement that all patients are supervised by a doctor.
Ask what side effects or changes should prompt contact and how to reach the clinician. Clarify which concerns are urgent. Chest pain, a seizure, collapse, severe confusion, serious breathing difficulty, or immediate danger of self-harm requires emergency help. Do not wait for a routine prescribing appointment if a serious change occurs.
Also ask what happens if the medication is not helping, if it is difficult to take as directed, or if cocaine use continues. Honest reporting is important for reassessment. A plan should explain the review process rather than leave you to increase doses, stop treatment abruptly, or add other substances in response to disappointment.
Keep the prescriber’s role and the program’s role clear
If treatment occurs in a residential program, ask who writes the prescription, who monitors it, and who takes responsibility after discharge. A visiting clinician may be involved, but the arrangement should be explicit. Confirm whether the current prescriber and future clinician will receive the relevant assessment and treatment record with appropriate consent.
If a medication process extends beyond the planned stay, ask how continuity is arranged. The end of an accommodation package is not necessarily the end of a clinical treatment process. Identify the next appointment, pharmacy arrangements, and contact route for problems. Do not assume that a discharge prescription guarantees ongoing specialist review.
Our guide to ongoing treatment after stabilization explains how to connect the immediate episode to longer-term care. Medication is one part of that handoff. The next team also needs to understand current symptoms, treatment goals, behavioral work, and any unresolved diagnostic questions.
Separate treatment benefit from a change in one symptom
Before a trial of prescribed treatment, agree which outcomes matter. A medicine could improve a co-occurring symptom without changing cocaine use, or cocaine use could improve while another concern still needs attention. These are different findings. Ask the clinician to explain how the relevant outcomes will be recorded without treating every improvement as proof of the same effect.
For example, bring a brief account of sleep, daily functioning, cravings, and any use since the last appointment if those measures are relevant to your plan. Record difficult effects as well as hoped-for benefits. Avoid changing several medicines or adding supplements on your own to make the result clearer. A coordinated review can distinguish uncertainty from a reason to alter treatment and can keep appropriate care for another condition in place.
Evaluate research claims carefully
A clinical trial tests an intervention; it does not establish that the intervention works or is approved. If you are considering a trial, ask about eligibility, the study’s purpose, possible randomization or placebo, expected visits, risks, and what care continues outside the study. Participation should be an informed decision with the research team.
Do not confuse a promising laboratory finding, an early small study, and a well-established treatment outcome. Ask whether results have been published, what outcome was measured, and how the findings relate to the exact claim made by a provider. Testimonials cannot substitute for that evidence, and a medicine approved for another condition is not automatically approved for cocaine use disorder.
Supplements and wellness products also need scrutiny. Ask what is in the product, what evidence supports the intended use, who reviews interactions, and whether it is optional. Do not assume that natural means safe or that a costly infusion provides a benefit for cocaine use. Keep all products visible in the medication review.
Make the next prescribing conversation concrete
Bring three questions: what is the target, why this option, and how will we know whether to continue? Add your priorities, such as avoiding a particular adverse effect, improving daily functioning, or keeping an established condition stable. These details help the clinician weigh the options in a way that is relevant to you.
Before leaving, understand the current instructions, the monitoring plan, the next review, and how medication fits with behavioral care. A responsible discussion can acknowledge that there is no FDA-approved cocaine medication while still addressing treatable symptoms and co-occurring conditions. The goal is an evidence-informed, individualized plan whose purpose and limits remain clear.
Sources and further reading
Found a detail that has changed? Tell the editorial team.